



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (15<sup>th</sup> November)

# MEDICINAL CANNABIS DISTRIBUTION AGREEMENT SIGNED WITH MAJOR EUROPEAN SUPPLIER

## Key Points:

- ❖ **THC's wholly-owned subsidiary Candeo Limited signs agreement with European medicinal cannabis producer Endoca to distribute cannabis delivery systems throughout Australia**
- ❖ **Endoca is a recognised leader in the supply of high quality CBD products worldwide**
- ❖ **Significant step forward in distributing high quality medicinal cannabis products through European pioneers in extraction and purification**
- ❖ **This agreement provides a solid platform to expand the company's activities including its focus on rapid commercialisation.**

**The Hydroponics Company Limited** (ASX:THC) ("THC" or "the **Company**") as reported in our September quarterly report, that Candeo was in final negotiations for the supply of Medicinal Cannabis Products from a leading overseas partner is pleased to announce that Candeo Limited has signed a distribution agreement with Endoca B.V., a European provider of high quality pharmaceutical grade medicinal cannabis, to distribute medicinal cannabis products into Australia.

Endoca is one of Europe's most highly respected suppliers of GMP certified medicinal cannabis, with sales exceeding 50 million euro per annum. Initial products imported to Australia will include CBD oil, CBD capsules and a unique CBD + CBDA oil.

Commenting on the agreement, THC's Group Chief Executive Officer, David Radford, said: "The distribution agreement with Endoca is an important milestone for THC and Candeo in its program



The Hydroponics Company Limited  
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime St  
Sydney, NSW, Australia. 2000.

to deliver medicinal cannabis solutions into Australia. We are very pleased that Endoca recognises Candeo as the right partner for distributing medicinal cannabis solutions and we look forward to developing this relationship as more Australian doctors and patients seek a positive way forward with medicinal cannabis.”

Endoca CEO and Founder Henry Vincenty said: “I’m proud and at the same time very excited to finally being able to offer the Australian people a safe and high quality solution of medical cannabis through our competent partner Candeo.”

David Radford added : “Candeo’s strategy to bring the world’s best medicinal cannabis products and knowledge while building Australian production and supply capability has reached an important milestone. Candeo is very pleased that Australian doctors and patients will soon be able to access these very high quality products.”

**For further information, please contact:**



David Radford  
Group Chief Executive Officer  
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177  
**M:** +61 407 218 922  
**E:** davidr@thcl.com.au



Michael Lovesey  
Director Corporate Media Relations  
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177  
**M:** +61 449 607 636  
**E:** michaell@mrrcorporate.com

**About The Hydroponics Company** [www.thcl.com.au](http://www.thcl.com.au)

THC is at the forefront of developing a leading, diversified worldwide cannabis business, focused on the development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients.

**About Candeo Ltd** [www.candeo.com](http://www.candeo.com)

Candeo is a wholly-owned subsidiary of THC that operates under a pharmaceutical model with a focus on the end-to-end supply of medicinal cannabis products. The Company has leading expertise in breeding, growth and extraction capability with a focus on the rapid introduction of medicinal cannabis products, receiving a Cannabis Research Licence in July 2017 and a Medicinal Cannabis Licence in November 2017. Candeo leverages +17 years of Cannabis sativa breeding, variety selection and growth management. Candeo will target multiple medical markets with cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

**About Endoca** [www.endoca.com](http://www.endoca.com)

Endoca's primary focus is to research and develop innovative Cannabis extracts that can help to balance the human Endocannabinoid system making them accessible world-wide. We believe that through targeting the human Endocannabinoid system we can help many people on this planet to restore their internal balance. We are dedicated to producing the finest and purest quality products like CBD oil while never compromising on quality.